{"schema_version":"secwatch.filing_event.v1","accession":"0001447362-22-000092","form_type":"8-K","ticker":"CSTL","cik":"0001447362","company_name":"CASTLE BIOSCIENCES INC","filed_at":"2022-06-03T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.761528+00:00","generated_at":"2026-06-25T04:41:55.716023+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Castle Biosciences files updated pro forma financials for Cernostics acquisition","bullets":["Pro forma net loss of $38.9M for FY2021, including $3.6M in transaction accounting adjustments.","Pro forma revenue of $94.7M, reflecting Cernostics' $0.6M contribution.","Pro forma diluted loss per share of $1.55, compared to Castle standalone $1.24.","Pro forma operating loss of $47.7M, up from $40.1M standalone."],"urls":{"canonical":"https://secwatch.observer/filing/0001447362-22-000092","json":"https://secwatch.observer/filing/0001447362-22-000092.json","markdown":"https://secwatch.observer/filing/0001447362-22-000092.md","text":"https://secwatch.observer/filing/0001447362-22-000092.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447362/000144736222000092/0001447362-22-000092-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447362/000144736222000092/cstl-20220603.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T04:41:55.716023+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}